Primary Pigmented Nodular Adrenocortical Disease (PPNAD): A Patient Guide
At a Glance
PPNAD is a rare condition in which tiny adrenal nodules cause cortisol excess that can come and go, so scans may look normal. Repeated hormone testing can support diagnosis, and removing both adrenal glands controls cortisol but requires lifelong hormone replacement and adrenal-crisis planning.
Primary Pigmented Nodular Adrenocortical Disease (PPNAD) is an exceptionally rare and complex condition that causes the adrenal glands to overproduce the hormone cortisol. Cushing’s syndrome is the general term for cortisol excess and can have many causes, including exposure to prescribed steroid medications. Unlike some endogenous forms of Cushing’s syndrome—such as Cushing’s disease, which is driven by a pituitary tumor in the brain—PPNAD is ACTH-independent [1]. This means the adrenal glands act on their own without external signals.
The condition is characterized by the development of multiple tiny, dark-colored nodules within the adrenal glands. Because these nodules are often only a few millimeters in size, they can be difficult to detect on standard imaging like CT or MRI scans, which frequently appear entirely normal despite severe hormonal imbalances [2][3].
The behavior of PPNAD is often “quiet” or cyclic, meaning cortisol levels may rise and fall in waves rather than staying constantly high [4]. This makes the diagnostic journey challenging, as standard hormone tests may occasionally return normal results even when the disease is present. Diagnosis requires a high index of clinical suspicion and repeated biochemical testing guided by an endocrinologist. In selected cases, specialists may use multi-day dexamethasone testing (such as the Liddle test), which can reveal a paradoxical rise in cortisol levels that may support the diagnosis in certain clinical contexts [5][6].
In many cases, PPNAD is the first sign of a broader genetic syndrome known as Carney Complex [7]. This connection is typically driven by a pathogenic germline mutation in the PRKAR1A gene [8]. Because this mutation can affect various tissues throughout the body, PPNAD is often considered a multi-system issue that requires a holistic approach to care. This includes looking beyond the adrenal glands to monitor other potential manifestations, most notably non-cancerous heart tumors called cardiac myxomas [9][10].
The standard of care for resolving the cortisol excess in PPNAD is a bilateral adrenalectomy, or the surgical removal of both adrenal glands [11]. While this surgery is a definitive cure for the hypercortisolism, it marks the beginning of a new phase of life centered on survivorship and careful management. Following surgery, patients must take lifelong hormone replacement medications to perform the functions the adrenal glands once handled. This requires a dedicated commitment to daily dosing and a deep understanding of how to prevent adrenal crisis during times of physical stress or illness [12][13].
Ultimately, living with PPNAD is a journey of vigilance and partnership with a specialized medical team. By combining consistent hormone replacement therapy with individualized screenings for other features of Carney Complex, patients can effectively manage the risks associated with the disease [14][15].
In this guide
6 chapters
Understanding Primary Pigmented Nodular Adrenocortical Disease (PPNAD)
Learn about primary pigmented nodular adrenocortical disease (PPNAD): its symptoms, excess cortisol, ACTH, CT, and PRKAR1A tests, and the link to Carney Complex
Recognizing the Symptoms and Warning Signs of PPNAD
Learn to recognize PPNAD symptoms, including cyclic Cushing’s, growth changes, skin spots, bone problems, high blood pressure, and when to seek urgent care.
Getting an Accurate Diagnosis: Testing and Imaging
Learn how primary pigmented nodular adrenocortical disease (PPNAD) is diagnosed with repeated cortisol tests, ACTH, imaging, Liddle testing, and genetics.
Managing PPNAD: Surgical and Medical Options
Learn how PPNAD treatment works, including bilateral adrenalectomy, cortisol-lowering medicines, lifelong hormone replacement, and recovery expectations.
Crisis Management: Navigating Adrenal Insufficiency Post-Surgery
Learn to manage adrenal insufficiency after PPNAD surgery: recognize crisis signs, follow sick-day rules, use emergency hydrocortisone, and keep a safety plan.
Long-Term Monitoring and Carney Complex Surveillance
Learn how PPNAD follow-up includes Carney Complex screening, genetic counseling, heart checks, hormone replacement, and bone health monitoring after surgery.
Common questions in this guide
What is primary pigmented nodular adrenocortical disease?
Can I have PPNAD if my CT or MRI scan looks normal?
Why can hormone tests sometimes miss PPNAD?
Is PPNAD connected to Carney Complex?
What should I expect after surgery to remove both adrenal glands?
Which specialists may be involved in PPNAD care?
Get notified when new evidence is published on pigmented nodular adrenocortical disease, primary, 1.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
ACTH independent Cushing's syndrome: Diagnosis and etiology.
Ortiz-Flores AE
Vitamins and hormones 2026; (132()):79-92 doi:10.1016/bs.vh.2026.02.001.
PMID: 42236016 - 2
Bilateral Adrenocortical Nodular Disease and Cushing's Syndrome.
Bouys L, Violon F, Louiset E, et al.
The Journal of clinical endocrinology and metabolism 2024; (109(10)):2422-2432 doi:10.1210/clinem/dgae419.
PMID: 38888184 - 3
Challenging Diagnostic Workup of a 22-year-old Patient With Primary Pigmented Nodular Adrenocortical Disease.
Wernig J, Pilz S, Trummer C, et al.
JCEM case reports 2024; (2(10)):luae174 doi:10.1210/jcemcr/luae174.
PMID: 39355138 - 4
Integrated clinical-genetic-pathological analysis expands the phenotypic and molecular spectrum of PPNAD across carney complex and isolated forms.
Kuhn AW, Lerario AM, Charchar HL, et al.
European journal of endocrinology 2026; (195(2)):217-228 doi:10.1093/ejendo/lvag137.
PMID: 42543523 - 5
Efficacy of dexamethasone suppression test during the diagnosis of primary pigmented nodular adrenocortical disease in Chinese adrenocorticotropic hormone-independent Cushing syndrome.
Chen S, Li R, Lu L, et al.
Endocrine 2018; (59(1)):183-190 doi:10.1007/s12020-017-1436-9.
PMID: 29094256 - 6
Update on primary micronodular bilateral adrenocortical diseases.
Maillet M, Bourdeau I, Lacroix A
Current opinion in endocrinology, diabetes, and obesity 2020; (27(3)):132-139 doi:10.1097/MED.0000000000000538.
PMID: 32209819 - 7
The clinical characteristics and pathogenic variants of primary pigmented nodular adrenocortical disease in 210 patients: a systematic review.
Sun J, Ding L, He L, et al.
Frontiers in endocrinology 2024; (15()):1356870 doi:10.3389/fendo.2024.1356870.
PMID: 39006359 - 8
Genetics of micronodular adrenal hyperplasia and Carney complex.
Tirosh A, Valdés N, Stratakis CA
Presse medicale (Paris, France : 1983) 2018; (47(7-8 Pt 2)):e127-e137 doi:10.1016/j.lpm.2018.07.005.
PMID: 30093212 - 9
Frequency and Incidence of Carney Complex Manifestations: A Prospective Multicenter Study With a Three-Year Follow-Up.
Espiard S, Vantyghem MC, Assié G, et al.
The Journal of clinical endocrinology and metabolism 2020; (105(3)) doi:10.1210/clinem/dgaa002.
PMID: 31912137 - 10
Recurrent left atrial myxoma in Carney complex: A case report of a familial pedigree.
Wang L, Wang Q, Zhou Y, et al.
Medicine 2018; (97(12)):e0247 doi:10.1097/MD.0000000000010247.
PMID: 29561454 - 11
Cushing´s syndrome due to bilateral adrenal cortical disease: Bilateral macronodular adrenal cortical disease and bilateral micronodular adrenal cortical disease.
Araujo-Castro M, Marazuela M
Frontiers in endocrinology 2022; (13()):913253 doi:10.3389/fendo.2022.913253.
PMID: 35992106 - 12
PRKAR1A-negative familial Cushing's syndrome: two case reports.
Lim LL, Kitan N, Paramasivam SS, et al.
Journal of medical case reports 2015; (9()):277 doi:10.1186/s13256-015-0757-7.
PMID: 26619967 - 13
Perioperative Risks and Long-Term Outcomes of Bilateral Adrenalectomy: A Multicenter Retrospective Cohort Study Across Cushing's Syndrome and Non-Cushing Etiologies.
Güngör Semiz G, Yılmaz N, Aydemir M, et al.
Medicina (Kaunas, Lithuania) 2026; (62(7)) doi:10.3390/medicina62071373.
PMID: 42512915 - 14
Cushing's syndrome due to primary pigmented nodular adrenal disease in two brothers with Carney complex.
Attri B, Aggarwal A, Mattoo S, Kulshreshtha B
Pediatric endocrinology, diabetes, and metabolism 2020; (26(3)):155-158 doi:10.5114/pedm.2020.95625.
PMID: 32901471 - 15
PRIMARY PIGMENTED NODULAR ADRENOCORTICAL DISEASE (PPNAD) PRESENTING AS CUSHING SYNDROME IN A CHILD AND REVIEW OF LITERATURE.
Bavadiya G, Roy A, Sarkar KK, et al.
Acta endocrinologica (Bucharest, Romania : 2005) 2020; (16(3)):362-365 doi:10.4183/aeb.2020.362.
PMID: 33363661
This page is for informational purposes only and does not constitute medical advice. It cannot replace personalized guidance from an endocrinologist, surgeon, genetic counselor, or other clinician about PPNAD and hormone replacement.